COVID-19 vaccine effectiveness
If you want to see all comparisons, please click here
ChAd/BNT-28 vs ChAd/ChAd-28
You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.
|Trial||Type||Comparisons||Design||Participants||Sample size||Overall risk
|Intervention 1||Intervention 2|
ISRCTN69254139, EudraCT: 2020-005085-33
AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma
Liu X, SSRN, 2021
|RNA based vaccine||RCTPhase 2||Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK||N=463||